Editorial illustration for DeepMind spinoff’s AI‑designed drugs enter human trials after AlphaFold 3
AI Drug Discovery Breakthrough Enters Human Trials
DeepMind spinoff’s AI‑designed drugs enter human trials after AlphaFold 3
The protein-folding models were always destined for the real world. That was the whole point. Now a spinoff from DeepMind is pushing drugs designed by its Nobel-winning AI into human trials.
In 2024, DeepMind and Isomorphic Labs released AlphaFold 3, which advanced scientists' understanding of proteins even further. It moved beyond modeling proteins in isolation to predicting other important molecules, such as DNA and RNA, and their interactions with proteins. "This is exactly what you need for drug discovery: You need to see how a small molecule is going to bind to a drug, how strongly, and also what else it might bind to," Hassabis told WIRED at the time.
Since its release, the AlphaFold platform has been able to predict the structure of virtually all the 200 million proteins known to researchers and has been used by more than 2 million people from 190 countries. The breakthrough earned Hassabis and Jumper the Nobel Prize for chemistry in 2024, with the Nobel committee noting that AlphaFold has enabled a number of scientific applications, including a better understanding of antibiotic resistance and the creation of images of enzymes that can decompose plastic.
That transition from academic triumph to clinical asset is the critical one. For years, computational biology was a field of beautiful simulations and distant promises. AlphaFold 3 provided a key piece of the puzzle by showing not just a protein’s shape, but how a drug might lock into it.
This moves the initial, most speculative phase of discovery from a wet lab bench into a digital simulation. You can fail faster and cheaper there. Most of these AI-designed molecules will still flame out.
They always do. The true test is whether this method yields a higher percentage of viable candidates, or shaves meaningful time off a process that normally takes a decade and costs billions. The map is drawn.
Now we see if it leads to a cure.
Related Reading
Browse all Google news →
Research & Benchmarks Google's FACTS benchmark shows 70% factuality ceiling across four tests
Research & Benchmarks Databricks finds multi-step agents beat single-turn RAG by 21% to 38% on STaRK
Research & Benchmarks Nvidia's DLSS 4.5 beta adds 6x Multi Frame Generation for RTX 50 GPUs
Related Topic NVIDIA and Google Cloud let developers scale AI from prototype to production
Market Trends
Related Topic Google tests visual 'magazine-style' UI for Gemini 3 Pro users
LLMs & Generative AI
From Archives COALA paper defines agent memory types: procedural rules and semantic facts
From Archives Google DeepMind's Decoupled DiLoCo hits 88% goodput despite hardware failures
From Archives Google Cloud AI launches ReasoningBank with MaTTS memory-aware scaling
Policy & Regulation
From Archives Google unifies Gemini Enterprise Platform and Application in new release
Business & Startups
Common Questions Answered
How did AlphaFold 3 advance drug discovery capabilities?
AlphaFold 3 expanded protein modeling beyond isolated proteins to predict interactions between proteins, DNA, and RNA. This breakthrough allows scientists to better understand molecular interactions, which is crucial for designing more effective drug compounds.
What milestone has Isomorphic Labs achieved in AI-driven drug development?
Isomorphic Labs has moved its first computer-crafted drug compounds into human clinical trials, marking a significant step in AI-powered pharmaceutical research. These compounds were entirely generated by algorithmic models that map protein behaviors and molecular interactions.
What makes Isomorphic Labs' approach to drug discovery unique?
Isomorphic Labs uses advanced AI algorithms derived from DeepMind's protein-folding work to design drug compounds, moving beyond traditional drug discovery methods. Their approach leverages machine learning to predict molecular interactions and potential drug efficacy before traditional laboratory testing.
Further Reading
- Google DeepMind's Spinoff Company 'Very Close' to Human Trials for Its AI-Designed Drugs — Slashdot
- Isomorphic Labs has grand ambitions to 'solve all diseases' with AI — Fortune
- Isomorphic Labs prepares to launch trials for AI-designed drugs — Clinical Trials Arena
- Review of AlphaFold 3: Transformative Advances in Drug Design — PMC/NIH
- AlphaFold3: Revolutionizing drug discovery and development — Labiotech.eu
